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Abstract
Background: Cutaneous peripheral neuropathies have been associated with changes of the sensory fiber
innervation in the dermis and epidermis. These changes are mediated in part by the increase in local expression of
trophic factors. Increase in target tissue nerve growth factor has been implicated in the promotion of peptidergic
afferent and sympathetic efferent sprouting following nerve injury. The primary source of nerve growth factor is
cells found in the target tissue, namely the skin. Recent evidence regarding the release and extracellular maturation
of nerve growth factor indicate that it is produced in its precursor form and matured in the extracellular space. It is
our hypothesis that the precursor form of nerve growth factor should be detectable in those cell types producing
it. To date, limitations in available immunohistochemical tools have restricted efforts in obtaining an accurate
distribution of nerve growth factor in the skin of naïve animals and those with neuropathic pain lesions. It is the
objective of this study to delineate the distribution of the precursor form of nerve growth factor to those cell types
expressing it, as well as to describe its distribution with respect to those nerve fibers responsive to it.
Results: We observed a decrease in peptidergic fiber innervation at 1 week after the application of a chronic
constriction injury (CCI) to the sciatic nerve, followed by a recovery, correlating with TrkA protein levels. ProNGF
expression in CCI animals was significantly higher than in sham-operated controls from 1-4 weeks post-CCI. ProNGF
immunoreactivity was increased in mast cells at 1 week post-CCI and, at later time points, in keratinocytes. P75
expression within the dermis and epidermis was significantly higher in CCI-operated animals than in controls and
these changes were localized to neuronal and non-neuronal cell populations using specific markers for each.
Conclusions: We describe proNGF expression by non-neuronal cells over time after nerve injury as well as the
association of NGF-responsive fibers to proNGF-expressing target tissues. ProNGF expression increases following
nerve injury in those cell types previously suggested to express it.
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Background
Nerve growth factor (NGF) is a 13 kDa neurotrophin
[1]. Its roles within the peripheral nervous system
include the maintenance of the adult sensory afferents
and sympathetic post-ganglionic efferents [2,3]. During
embryonic development, its expression is essential for
the normal development and maturation of the sympa-
thetic nervous system [4]. Mice engineered to over-
express NGF in keratinocytes were associated with
increased peptidergic fiber density as well as inappropri-
ate innervation by sympathetic efferents [5,6]. These
mice were also shown to have heightened sensitivity to
applied heat and mechanical stimuli [7]. We have pre-
viously demonstrated that following nerve injury, there
was an increase in sympathetic and peptidergic innerva-
tion in skin, comparable to that occurring following the
overexpression of NGF [8-12]. We have also shown that
an increase in sympathetic and peptidergic innervation
occurs following application of nerve injury models
[8-10]. These observed changes in NGF-responsive
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sympathetic and sensory fibers have been proposed to
be mediated through the cell-surface NGF receptors, the
high affinity receptor TrkA and the low-affinity pan-
neurotrophin receptor p75 [13]. In agreement with this,
TrkA and, to a lesser extent, p75 were detected in both
post-ganglionic sympathetic efferents and peptidergic
sensory afferents [14,15]. However, p75 was mainly
expressed on Schwann cells, a cell type which is in
direct contact with the nerve fibers [16]. Dimeric NGF
binds its cognate receptor, TrkA and upon complex for-
mation with p75, TrkA undergoes a conformational
change enhancing its binding affinity for NGF [17-20].
The half-life of NGF binding to p75 is very rapid such
that dissociation times have been estimated at < 3 sec
[20-22]. NGF is synthesized by a variety of peripheral
cell types including mast cells, lymphocytes, keratino-
cytes and vascular endothelium in its precursor form
proNGF [23-28]. The receptor p75 has a high affinity
for proNGF, unlike its mature form (mNGF), and when
ligand bound, engages pro-apoptotic signaling cascades
[29,30]. Keratinocytes have been demonstrated to
express a number of ligand-gated ion channels such that
upon ligand binding, cause membrane depolarization
and release of a variety of factors including proNGF and
ATP [31-33]. Within the extracellular space, proNGF is
converted to its mature form, mNGF, through a pro-
tease cascade [34]. The enzymes involved in this cascade
include plasminogen, which is converted to its active
form, plasmin, by either tPa or uPa. Plasmin in turn
converts proNGF into its mature form, mNGF, and also
converts proMMP-9 to its mature form, MMP-9, which
in turn degrades mNGF [34,35]. Previous literature
describing the distribution of NGF in the periphery has
been restricted to studies following injury, a point in
which NGF is detectable within responsive nerve fibers
[36] other than an early study examining the distribu-
tion of NGF in keratinocytes [27]. A clear differentiation
between proNGF and mNGF could not be made in the
above mentioned examples since the antibody used can-
not differentiate the mature from the precursor form.
Following nerve injury, Wallerian degeneration is trig-
gered, a process necessary for those axons directly
affected by the ligature and experiencing demyelination
to be successfully cleared of myelin debris by recruited
macrophages as well as for subsequent sprouting of
uninjured axons [37]. During the process of Wallerian
degeneration, macrophages and mast cells are recruited
to the site of injury [38] where their phagocytic capabil-
ities assist in clearing myelin debris [38]. Activation of
local Schwann cells is followed by increased production
of Il-1b and TNF-a, both of which increase transcrip-
tion and translation of NGF within local cell types
[23,39-41]. This increase in peripheral Il-1b and TNF-a
takes on additional significance when it is considered
that they can lead to increases in proMMP-9 protein
levels as well as its conversion to the mature form
within skin; it has also been shown that cell surface
plasmin levels were also increased following the increase
in Il-1b and TNF-a [42-44]. It has long been known
which cell types are responsible for the production of
NGF; however these studies have employed indirect
methods such as culturing, in situ hybridization or over-
expression systems [24,38,45,46].
NGF has been strongly implicated in both neuropathic
and inflammatory pain conditions [47-51]. It has been
shown that following activation of Schwann cells as part
of the Wallerian degeneration response, Schwann cells
dramatically upregulate p75 on their cell surface
[16,52,53]. The exact role of this upregulation has not
been clearly defined, although it has been proposed that
p75 in this case acts as a sequestering molecule to keep
the increased NGF on the cell surface, to facilitate its
function as a chemo attractant molecule for regenerat-
ing peptidergic afferents [53,54].
The increase in available NGF associated with both
neuropathic and inflammatory pain has been well docu-
mented [38,51,55-57]. Mice engineered to over-express
NGF in keratinocytes not only develop hyperinnervation
in the target tissue region by peptidergic afferents and
sympathetic efferents but also display sympathetic bas-
ket formation around populations of dorsal root ganglia
neurons [5,58].
Our lab has consistently demonstrated that following
nerve injury there is a dramatic initial loss of myelinated
and unmyelinated sensory afferents [8-10,12]. Four
weeks following application of the chromic gut-based
chronic constriction nerve injury, there was a return to
sham operated control of peptidergic afferents followed
by the development of a significant increase in peptider-
gic fiber density at later stages [8,12]. We also detected
a sprouting of sympathetic efferents into the upper der-
mis, a territory from which they are normally devoid,
and which not only innervated areas of the dermis away
from blood vessels but associated very closely with pep-
tidergic afferents [8].
We undertook the current study to test the hypothesis
that, following nerve injury, the innervation changes of
peptidergic afferents and sympathetic efferents follow a
change in expression of proNGF in the periphery and




To study the normal distribution of proNGF immunor-
eactivity, we used bright field microscopy (Figure 1A).
proNGF immunoreactivity was detected in well defined
but sparse patches as a brown DAB precipitate in the
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epidermis and dermis. In the epidermis, proNGF immu-
noreactivity was restricted to small patches of labeled
keratinocytes along the dermo-epidermal junction (Fig-
ure 1A; arrowhead). Mast cells were identified based on
metachromatic staining of heparin in granules using
toluidine blue. In sections from control animals, mast
cells were not abundant in the upper dermis and were
only faintly immunoreactive for proNGF (not shown).
proNGF was also found in the endothelium of capillaries
and venules, identified based on the flattened appear-
ance of the cells outlining the vessel lumen, and in peri-
vascular cells (Figure 1A). One week post-CCI, the mast
cell number qualitatively increased in the upper dermis
and these cells were proNGF immunoreactive (Figure
1B; arrow). Two weeks following nerve lesion, mast cell
infiltration in the upper dermis decreased, however
proNGF immunoreactivity increased in other non-neu-
ronal structures, including the vascular endothelium,
fibroblasts and, particularly, keratinocytes (Figure 1C).
The results at four weeks post-lesion were similar to
those at two weeks, although labeling of keratinocytes
was much less (Figure 1D). Pre-incubation of the anti-
body with its control peptide abolished all specific stain-
ing (Figure 1E).
Western blots were done in order to more accurately
quantify this change in expression levels of proNGF pro-
tein itself rather than indirectly through levels of inten-
sity of bright-field images (Figure 1F). The sampled
protein was taken from the same area of the glabrous
skin in which immunohistochemistry was conducted.
Figure 1 Distribution of proNGF immunoreactivity in naïve glabrous skin and following application of CCI. A) In sham operated controls,
proNGF (brown precipitate) was found in the upper dermis, particularly in wall of blood vessels, and in small patches of keratinocytes
(arrowhead). B) 1 week post-injury, proNGF immunolabeling was detected in mast cells (arrows; identified based on toluidine blue
metachromatic counterstaining), in blood vessels in the upper dermis as well as in keratinocytes. C) At 2 weeks post-injury, note the intense
immunostaining of keratinocytes, the labeling of some unidentified structures in dermis and a lower number of immunostained mast cells. D) At
4 weeks post-injury, note mast cell immunolabeling. E) Preincubation of antibody with control peptide abolished all specific staining. F) proNGF
quantification was done by Western Blot analysis (n = 6) from sham, and animals 1 - 4 week post-injury. OD was normalized against b-actin
loading controls. ***p < 0.001, **p < 0.01, *p < 0.05; +SEM.
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Care was taken during sample extraction and prepara-
tion to ensure no contaminating protein from cartilage
or deep tissues such as striated muscle. Data from the
Western blots demonstrate an increase in target tissue
levels of proNGF at one week post-injury, with a further
increase at two to four weeks (Figure 1F). These results
taken together indicate that the increase in proNGF at
one week post-injury is predominantly from infiltrating
mast cells whereas at two weeks post-injury this increase
in target tissue levels of proNGF has switched to kerati-
nocytes and blood vessels.
It has long been shown that p75 is expressed on the
surface of Schwann cells and that this expression is
upregulated following nerve injury [16]. To confirm and
expand this observation, S100 was used as a marker for
Schwann cells at the light microscopy level in a co-
staining for p75 to show the distribution of the receptor
on Schwann cells following nerve injury. In sham oper-
ated animals, S100 immunoreactivity was present with
varying intensities depending on location (Figure 2A, in
green). Thicker cutaneous nerves, further from the
dermo-epidermal junction, were most intensely labeled,
likely because they are rich in A-fibers surrounded by
myelinating Schwann cells, in which S100 content is
known to be high. We also observed some S100
immmunostaining, usually not very intense, along the
dermo-epidermal junction which might represent non-
myelinating Schwann cells associated with C-fibers,
which are known to contain less S100 protein than mye-
linating Schwann cells [59]. P75 receptor immunoreac-
tivity (in red) in sham-operated controls was low and
often surrounded S100-IR structures, likely representing
immunostaining in perineurial cells; it was also occa-
sionally seen within the S100-IR structures, possible
representing p75 expression on sensory axons (Figure
2A; arrow). One week following nerve injury (Figure
2B), the relative intensity of p75 to S100 changed dra-
matically as p75 immunoreactivity was significantly
more intense than that of S100, correlating with the sig-
nificant increase in protein content (see Figure 3). At
two to four weeks post injury (Figures 2C-D), S100 and
p75 immunoreactivities were both intense and heavily
co-localized. The co-localization of the two immunor-
eactivities occurred at all time points studied post-
injury. A triple labeling showing p75, S100 and proNGF
immunoreactivities (Figure 2E-F) in sham-operated and
at two weeks post-injury allowed us to show the distri-
bution of each of these immunoreactive structures with
respect to the other either before or after injury. It was
found that in sham operated controls that p75 and S100
immunoreactivity are found within the same nerve fiber
bundles, where S100 was more intense than that of p75.
However, after injury, proNGF immunoreactivity
increased in vascular endothelial-like structures and
keratinocytes, whereas strong p75 immunoreactivity was
seen in Schwann cells. Importantly however, a co-locali-
zation between p75 on Schwann cells and proNGF was
not observed.
Changes in NGF-Responsive Fiber Innervation
Due to the known cell surface expression of the high-
affinity TrkA receptor and of p75 on both post-ganglio-
nic sympathetic efferents and sensory peptidergic affer-
ents, we sought to determine what relationship existed
between proNGF producing cell types and these fibers
in sham operated controls and after nerve injury (Figure
4). We observed that the post-ganglionic sympathetic
efferent population, as detected by DbH immunoreactiv-
ity, seemed to innervate proNGF-IR structures (Figure
4A). In sham operated controls, the DbH-IR fibers
appeared to wrap around the proNGF-IR cells in the
wall of presumptive blood vessels. At one and two
weeks post-injury, the association of DbH-IR fibers with
proNGF producing cells remained similar to sham in
that there was either a restriction of the DbH-IR fibers
to the lower dermis (Figure 4B) or a close association
between the DbH-IR fibers with blood vessels (Figure
4C). However, at four weeks post-injury, a time point
when our lab has previously reported a significant pre-
sence of sympathetic efferents in the upper dermis away
from blood vessels [8,9], we observed that DbH-IR fibers
still innervated proNGF producing structures; however,
the sections of the fibers closer to the epidermis were
not associated with proNGF (Figure 4D). In sham-oper-
ated animals, the peptidergic, CGRP-IR afferents were
also seen to have segments close to proNGF producing
structures, but the association of the two was not as
obvious as for the sympathetic (Figure 4E). At one week
post-injury, a time point at which CGRP-IR afferent loss
was maximal; there was no association between the
remaining CGRP-IR fibers and proNGF-IR structures
(Figure 4F). At two weeks post-injury, however, there
was an obvious association between CGRP-IR fibers and
proNGF producing cells (Figure 4G). Interestingly, at
four weeks post-CCI, a time point at which peptidergic
afferents returned to sham-operated levels [8,12], the
association was not as close as that observed at two
weeks (Figure 4H).
P75 association with other structures
We have also investigated the association of nerve fibers
identified with the pan-neuronal marker, PGP-9.5, with
p75 expression (Figure 5). In sham operated controls,
PGP-9.5-IR nerve fibers were distributed throughout the
epidermis and in the upper dermis and formed a dense
plexus (Figure 5A). In the lower dermis, PGP9.5-IR
fibers were found in small cutaneous nerves with a
sheath of p75 immunoreactivity around them, likely
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Figure 2 Changes in p75 expression on S100-IR Schwann cells. A) In sham-operated rats Schwann cells (green) were detected by means of
S100 immunoreactivity in small nerves, with immunoreactivity of varying intensity from bright (arrow), lower in the dermis, to dim, along the
dermo-epidermal junction. P75 immunoreactivity (red) was evident surrounding all S100-IR Schwann cells. B) One week following nerve injury,
p75 immunostaining was dramatically upregulated in Schwann cells; the intense red color masked the mixture of red and green stainings which
could be detected by analysing the separately the S100 and p75 stainings (not shown). C-D) 2 & 4 weeks post-injury a decrease in p75 intensity
was observed in that the yellow indicative of S100 co-labelling was able to be visualized. E) proNGF (red) S100 (green) and p75 (blue) triple
labelling to demonstrate the relative distribution of Schwann cells with respect to proNGF; note a limited distribution of Schwann cells with
proNGF and faint immunoreactivity for p75 in sham-operated controls. F) 2 weeks post-injury, the clear upregulation of p75 immunoreactivity
associated with S100 (arrow) was observed, which wrapped around proNGF-IR blood vessels.
Peleshok and Ribeiro-da-Silva Molecular Pain 2012, 8:1
http://www.molecularpain.com/content/8/1/1
Page 5 of 15
Figure 3 Quantification of p75 protein content in glabrous skin. Glabrous skin was taken from the same region sampled for
immunocytochemistry. A single band corresponding to that of the PC12 cell culture supernatant used as positive control was observed. Note
the increased p75 protein levels particularly at 1-2 weeks post-lesion. OD was normalized against b-actin loading controls. N = 6; ***p < 0.001,
**p < 0.01, *p < 0.05; +SEM.
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representing staining of perineurial cells (Figure 5A).
Interestingly, PGP9.5-IR fibers penetrating the epidermis
were not associated with p75 immunoreactivity (Figure
5A). At one week post-nerve injury, there was scarce
PGP-9.5 immunoreactivity in the upper dermis, consis-
tent with previous reports of a dramatic decrease in
nerve fiber innervation at this time point [12] (Figure
5B). However, p75 was strongly upregulated (Figure 5B),
likely due to strong Schwann cell labeling (see Figure
2A). At later time points (Figure 5C-D), PGP9.5-IR
fibers were progressively more abundant and were asso-
ciated with p75 immunoreactivity. At one to four weeks
post-injury, PGP-9.5-IR structures in the epidermis
represented mostly Langerhans cells staining (Figure 5B-
D), as nerve fibers were mostly depleted from the
epidermis.
We also investigated the relationship of p75 with
respect to proNGF immunoreactivity. We found that in
Figure 4 Sympathetic and peptidergic nerve fibre association with proNGF. A) DbH-IR sympathetic efferents (red) were closely associated
with proNGF (green) in sham operated control animals. B-C) At 1 and 2 weeks post-injury, no detectable difference was observed in the pattern
of sympathetic efferent distribution with respect to proNGF. D) At 4 weeks post-lesion sprouted sympathetic efferents retained their association
with proNGF, and continued to sprout towards the dermo-epidermal junction. E) In sham-operated rats, peptidergic afferents were distributed
along the dermo-epidermal junction in which the occasional group of proNGF immunoreactive cells was found. F) At 1 week following nerve
injury, very few peptidergic afferents were observed. G) At 2 weeks post-injury, peptidergic afferents were found along the dermo-epidermal
junction as well as along proNGF immunoreactive cells (arrow). H) At 4 weeks post-lesion, peptidergic afferents increased in numbers were
loosely associated with proNGF-IR cells (arrow).
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the sham-operated controls (Figure 5E), proNGF-IR
patches within the upper dermis loosely associated with
p75-IR structures, however there was no colocalization
as indicated by the absence of yellow color. At one week
post-injury, the intensity of the p75 immunoreactivity
greatly surpassed that of proNGF (Figure 5F), and at
two and four weeks post injury, we were able to demon-
strate sparse p75 immunoreactive fibers in the epidermis
as well as in the upper dermis (Figure 5G-H).
Western Blot
The results of quantification of by Western blot of the
relative increase in p75 expression following nerve injury
are illustrated on Figure 3. Consistent with the immuno-
histochemical data, there was a very significant increase
in p75 expression at one week post-injury. The high
protein levels persisted at two weeks post-injury, and
were lower, although still elevated, at four weeks post-
CCI (Figure 3). The changes in p75 protein levels were
Figure 5 Distribution of p75 immunoreactivity following nerve injury and relationship to nerve fibers and proNGF. A) In sham-operated
animals, p75 was distributed (red) around and with PGP 9.5-IR nerve fibers (green). P75 staining was found more clearly around large cutaneous
PGP 9.5-IR nerve fiber bundles and smaller fibers along the dermo-epidermal junction. Where nerve fibers crossed the dermo-epidermal junction
into the epidermis, the yellow color representing p75 associating with nerve fibers was lost (arrow). B) At 1 week post-injury, virtually all PGP-9.5-
IR nerve fibers disappeared from the upper dermis and epidermis; immunostaining in p75-IR Schwann was very intense. C) At 2 weeks post-
injury, a low number of PGP-9.5-IR fibers were detected and were associated with p75 Schwann cells (yellow), however most of the PGP-9.5-IR
was restricted to Langerhans cells in epidermis (arrow) D) At 4 weeks post-injury, p75 immunoreactivity decreased co-incidentally with the
increase in PGP-9.5 immunoreactivityin the upper dermis (yellow). E-H) ProNGF and p75 association in sham-operated controls and in lesioned
animals was loose in that most proNGF immunoreactivity was segregated from that for p75 and there was no obvious co-localization (arrows).
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parallel to those seen using immunohistochemistry (Fig-
ure 2A-D & Figure 5).
The quantification of the changes in TrkA expression
within the glabrous skin of the rat hind paw was done
using Western Blot (Figure 6). We observed that a sig-
nificant decrease in TrkA protein content occurred at
one and two weeks following nerve injury with a recov-
ery at four weeks post-lesion. This is consistent with the
Figure 6 Quantification of TrkA protein content in glabrous skin. TrkA protein was sampled from glabrous skin of same region used for
immunocytochemistry. Two bands were recognized by the monoclonal anti-TrkA antibody, a 110 kDa and 140 kDa form corresponding to the
immature, unglycosylated form and mature form respectively. TrkA levels decreased significantly at 1 week post-injury and remained significantly
lower at 2 weeks post-injury until 4 weeks, at which point no difference was observed compared to sham-operated controls. OD is normalized
against b-actin loading controls. ***p < 0.001, **p < 0.01, *p < 0.05; +SEM.
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observation that peptidergic afferents retract from the
upper dermis and epidermis shortly after injury and
recover by four weeks [8,12].
Discussion
In this study, we performed for the first time a detailed
description of the relationship of the NGF-responsive
nerve fiber populations to the neurotrophin-producing
cells following the application of a commonly used neu-
ropathic pain model, the CCI of the sciatic nerve.
Because NGF is known to occur in cells in its precursor
form [34], proNGF, we used antibodies specific for this
precursor form.
Previous research has focused on the changes in
mature NGF uptake following nerve injury given that
mNGF is expressed at very low levels in target tissues in
sham or naïve animals [36]. Methods such as in situ
hybridization have shown that the mRNA for NGF is
transcribed in Schwann cells [24,45] and fibroblasts [60]
and that the protein exists in mast cells [26] and kerati-
nocytes [27]. Cultured mast cells have also been demon-
strated to upregulate NGF when presented with the
cytokines IL-1b and TNF-a [39,40,61], and when degra-
nulated release NGF into the culture media [26].
Schwann cell production of NGF has been demonstrated
using culturing methods in which morphology of
Schwann cells in explanted optic nerve has been shown
to correlate with NGF expression [45]. A line of evi-
dence that has pervaded research literature is that a che-
moattractant gradient of NGF created by its retention
through cell surface expressed low-affinity NGF recep-
tors, p75 [53,62]. However, due to the restrictions of the
available methodology, this has not yet been directly
proven.
In the current study we provide some important new
evidence, namely that a significant expression of
proNGF by Schwann cells, identified by S100 immunor-
eactivity, was not evident. We also show an association
of proNGF-producing cell types with NGF-responsive
sensory and sympathetic fibers. Consistent with a num-
ber of prior observations, we were able to confirm the
observed upregulation of p75 on non-neuronal cell
types, namely Schwann cells, following nerve injury
[16,23,63]. This upregulation was significant from early
time points. Also, we have been able to correlate an
immunocytochemical decrease in peptidergic innerva-
tion in the dermis and epidermis (the territories we
sampled by Western blotting) with TrkA protein levels.
Unfortunately, because of limitations of the availability
of a reliable, commercially available anti-TrkA antibody
for immunocytochemistry applications, we could not
study the detailed anatomical distribution of TrkA
immunoreactivity. TrkA levels in the skin can change
due to a number of reasons, namely by a decrease in
the level of expression in the cells or by a migration of
the TrkA-expressing cells to other territories. Previous
work from our lab and others demonstrate a retraction
or ‘dying back’ of peptidergic and non-peptidergic noci-
ceptive primary afferents from the epidermis and upper
dermis [64]. This has been demonstrated by examining
the distal regions of the common sciatic nerve following
application of the CCI in which axons can be shown to
degenerate, as well as by examining the upper dermis
directly using retrograde tracers and pan-neuronal mar-
kers [12,65]. The results of these studies strongly sug-
gest that the lack of peptidergic innervation is not due
to a decrease in phenotypic markers such as receptor or
peptide expression, but rather to fiber loss. It is also
TrkA expression on the regenerating afferents which
permits the regeneration to occur [66]. We have pre-
viously shown that peptidergic afferents return to inner-
vation density of sham-operated controls by four weeks
post-lesion, and that this recovery precedes that of any
other fiber population [12].
This report provides further evidence that Schwann
cells persist within the denervated territory. We have
previously shown at the light and electron microscopic
levels that following a complete transaction of a periph-
eral nerve, there was a complete loss of sensory fibers
from peripheral nerves and that the denervated
Schwann cells upregulate p75 in the absence of axon-
Schwann cell contact [16]. Our present data expands on
that observation by using a model in which there is a
partial nerve lesion and some axons remain uninjured
[67,68]. Indeed, in our material it was clear that from
one week post-lesion Schwann cells upregulated p75
and at two weeks post-injury those Schwann cells sur-
rounding either undamaged or regenerating nerve fibers
labeled with the pan-neuronal marker PGP-9.5.
A surprising result from this study is the lack of a dra-
matic upregulation of proNGF levels in Schwann cells.
Indeed, it has been suggested in many studies that, fol-
lowing nerve injury, Schwann cells would be among the
key producers of NGF and it would be mostly the NGF
from this source that would contribute to the sprouting
of peptidergic afferents within the periphery [53]. One
of our central premises is that cells immunoreactive for
proNGF are sources of NGF for responsive nerves.
Furthermore, that proNGF is released from the cells
into the extracellular space in an activity dependent
manner, and transformed into the active form, mNGF
[34]. One possibility might be that we are detecting only
proNGF and not mNGF, and that the latter form would
occur on Schwann cells. We can exclude that possibility
because mNGF occurs in very low concentrations even
after injury, as detected by Western blot using an anti-
body that recognizes both proNGF and mNGF [69].
Another possibility would be that the turnover of
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proNGF in Schwann cells is very high, meaning that the
relative lack of immunoreactivity could be indicative of
rapid rate of release rather than a lack of production.
Schwann cells, like keratinocytes, have been suggested
to express ion channels such as P2X receptors [70] and
sodium channels [71] and that upon activation depolar-
ize the cell’s membrane which could potentiate the
release of neuroactive molecules such as proNGF into
the intercellular space, but this does not explain why
proNGF can be detected on keratinocytes and not in
Schwann cells. However, based on the above, it is may
also be possible that Schwann cells represent only a
minor source of NGF.
We were also able to demonstrate a close association
between proNGF producing cells and NGF responsive
afferents from one to four weeks post-injury; these
include sympathetic efferents and peptidergic afferents.
There seemed to be a closer association between the
sympathetic fibers and proNGF-IR cells than between
peptidergic afferents and proNGF-IR cells. Historically it
has been shown that sympathetic efferents, rather than
sensory afferents are exquisitely responsive to changes
in levels of NGF in the environment and this was
demonstrated by neurite outgrowth when NGF was
added to culture media [4,72]. Our observations that
there was a closer association between the sympathetic
efferents and proNGF producing cell types than for the
peptidergic afferents may be reflective of the relative
degree of dependence or sensitivity of each fiber popula-
tion to NGF. It is thus not surprising that those struc-
tures which were more immunoreactive for proNGF
were blood vessels (Figure 1B, 2F, 4C), which are known
to receive dense innervation by sympathetic efferents
[73]. The changes after lesion in proNGF production are
consistent with the changes following the onset of Wal-
lerian degeneration, as within one week following nerve
injury we observed a large degree of mast-cell infiltra-
tion in the upper dermis (Figure 1B).
Conclusions
In summary, we were able to show that following appli-
cation of the traditional CCI model of neuropathic pain,
mast cells followed by keratinocytes and vascular
endothelium upregulate proNGF, and that this upregula-
tion was significant until at least four weeks post-injury,
as confirmed by Western blotting. This is in contrast to
the relative changes in TrkA protein levels and p75
within the same area. Following nerve injury, there was
a dying back of peptidergic afferents and a correlative
decrease in TrkA protein until four weeks post-injury,
at which point it returned to levels of sham-operated
animals, coinciding with the recovery of the peptidergic
innervation. Our data suggests that the sprouting after
lesion of NGF-responsive fibers is initiated by the
increase in local proNGF (and thus mNGF) levels, and
may be maintained with the involvement of other
factors.
Methods
In total, 60 male Sprague-Dawley rats (Charles River
Canada), weighing between 150-175 g, were used for
this study. All animals were maintained on a 12 hour
light/dark cycle and allowed access to food and water
ad libitum. All animal protocols were approved by the
McGill University Animal Care Committee and followed
the guidelines of the Canadian Council on Animal Care
and the International Association for the Study of Pain.
Peripheral Nerve Lesions
Animals were randomly assigned to receive either a tra-
ditional chronic constriction injury (CCI) or sham
operation. All animals were deeply anaesthetized with
isoflurane. In total, 30 rats received the sham operation
and 30 received the CCI injury to the common sciatic
nerve, as described in detail by Bennett & Xie [74].
Briefly, the left common sciatic nerve was exposed at
the mid-thigh through the biceps femoris. All surround-
ing fascia was removed to allow free passage to blunt
glass probes. Proximal to the trifurcation of the sciatic
nerve, four ligatures (4-0 chromic gut, Ethicon) were
tied loosely around the nerve with ~1 mm spacing in
between. The incision was closed in layers using absorb-
able sutures (Vicryl, Ethicon). The animals assigned to
sham-operated groups underwent the above mentioned
procedures with the exception of the application of the
chromic gut ligatures.
Animal perfusion and histological or Western blot
processing
Animals were sacrificed after periods of one, two, and
four weeks post-surgery. Rats were administered
Equithesin (6.5 mg chloral hydrate and 3 mg sodium
pentobarbital) in a volume of 0.3 mL, i.p., per 100 g
body weight. Three animals per time point were per-
fused for immunohistochemical analysis. Once animals
were deeply anesthetized, they were quickly transcar-
dially perfused with vascular rinse (0.1% w/v sodium
nitrite in a phosphate buffer) followed by histological
fixatives (3% paraformaldehyde, 15% saturated picric
acid in 0.1 M phosphate buffer pH 7.4) for 30 minutes.
The glabrous skin from the left hind paw, specifically
the thin skin surrounded by tori, was removed, post-
fixed for one hour in the same fixative used for the per-
fusion and placed in 30% sucrose in 0.1 M phosphate
buffer for cryoprotection overnight at 4°C. Tissue was
then embedded in an optimum cutting temperature
medium (OCT, TissueTek), cut using a cryostat (Leica)
at a thickness of 50 μm and processed as free floating
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sections. A second cohort of six animals per time point
were perfused for 30 seconds with ice cold saline to
clear contaminating blood. The same region of glabrous
skin as that used for immunohistochemistry was excised
from the rat hind paw, snap frozen in liquid nitrogen
and stored at -20°C for no more than ten days until pro-
cessed for Western blot analysis.
Immunohistochemistry
Sections were washed in PBS for 30 minutes. In all sub-
sequent steps, phosphate buffered saline (PBS) with
0.2% Triton X-100 (PBS-T) was used to dilute the
immunoreagents and for washing. Sections were treated
with 50% ethanol for 30 minutes followed by one hour
incubation in PBS-T containing 10% (v/v) normal serum
of the species used to generate the secondary antibody
to reduce non-specific staining. Subsequently, sections
were incubated with primary antibodies (diluted in PBS-
T) at 4°C overnight (or 48 hours in the case of S100).
The following primary antibodies were used: polyclonal
guinea-pig anti-human calcitonin gene related peptide
(CGRP; 1:4000, Bachem; Torrance CA), monoclonal
mouse anti-dopamine b-hydroxylase (DBH; 1:5 Medi-
Mabs, gift of Dr. A. Claudio Cuello), polyclonal rabbit
anti-proNGF (1:500, Alomone Labs, Israel), monoclonal
mouse anti-p75 (MC192; 1:5, Novus Biologicals), poly-
clonal rabbit anti-S100b (1:5000; Swant Switzerland) and
polyclonal rabbit anti-PGP 9.5 antibody (1:800, Cedar-
lane; Burlington Ont.). To assess by immunohistochem-
istry the specificity of the anti-proNGF antibody, we
pre-adsorbed it with the control antigen supplied by
Alomone (3 μg of control peptide to 0.8 μg of antibody)
for three hours over ice prior to incubation with control
tissue from naïve rats. After washing, the sections were
incubated with secondary antibody diluted in PBS-T for
two hours at room temperature. The following second-
ary antibodies were used: a) for those antibodies raised
in mouse, a highly cross-adsorbed goat anti-mouse IgG
conjugated to Alexa 596 (1:800, Molecular Probes,
Eugene, OR); b) for those raised in rabbit or guinea-pig,
a goat anti-rabbit or anti-guinea-pig conjugated to Alexa
488 (1:800, Molecular Probes, Eugene, OR); c) in the
case of the triple labeling a highly cross-adsorbed don-
key anti-mouse conjugated to Cy-5 (1:800, Molecular
Probes, Eugene, OR). Sections were washed and
mounted on gelatin-coated slides and coverslipped using
Aquapolymount (Polysciences; Warrington, PA). In the
case of S100 immunostaining, an hour incubation with
an goat anti-rabbit biotin conjugated secondary (1:400;
BA-1000; Vector) was used. Following this, sections
were incubated for one hour with the A and B reagents
(1:400 Vectastain ABC kit; Vector) followed by a two
hour incubation with a streptavidin antibody conjugated
to Alexa 488 (1:200; Molecular Probes, Eugene, OR).
For the S100/p75/proNGF triple labeling, the anti-
proNGF antibody was added following the completion
of the staining with S100 and p75. In the case of bright
field images using anti-proNGF antibodies, sections
were prepared as described above except for a ten min-
ute incubation with 0.1% H2O2 prior to blocking and
following incubation with primary antibody, incubated
for two hours with a biotinylated goat anti-rabbit sec-
ondary antibody (1:200, Vector). The sections were
washed with PBS and incubated for one hour with the
A and B reagents (4 μl of A + 4 μl of B per mL of PBS,
ABC Vectastain Elite kit). The sections were then
washed in PBS and incubated for 5 minutes in a solu-
tion of 3-3’-diaminobenzidine (Sigma, 5 mg for 10 ml of
PBS-T). Hydrogen peroxide was then added to the solu-
tion to reach a final concentration of 0.01%. The reac-
tion was terminated after ten minutes by the addition of
PBS. The sections were washed in PBS, mounted on
gelatin-subbed slides and air dried. Slides were rehy-
drated and briefly exposed to a 1% solution of toluidine
blue, rinsed and dehydrated in ascending alcohols and
xylene, then coverslipped with Entellan (EMD, Gibbs-
town, NJ).
Primary Antibody Characterization
CGRP: The anti-CGRP antibody raised in guinea pig
was purchased from Bachem (T-5027, lot A00098-2). It
was generated against a synthetic peptide from human
a-CGRP with the following sequence: H-Ala-Cys-Asp-
Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-
Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-
Pro-Thr-Asn-Val-Gly-Ser-Lys-Al a-Phe-NH2. The anti-
body has 100% reactivity with human and rat a-CGRP,
human CGRP (8-37), chicken CGRP, and human b-
CGRP. It has 0.04% crossreactivity with human amylin
and 0% crossreactivity with rat amylin and with human
and salmon calcitonin as determined by radioimmu-
noassay (manufacturer’s technical information).
Although Western blot information was not available,
the immunostaining has been localized in the skin to
IB4 negative C-fibers, and fibers innervating blood ves-
sels in rats [75,76] and in monkeys [77].
DbH: The anti-dopamine b-hydroxylase monoclonal
antibody was received as a gift from Dr. Claudio Cuello
(clone DBH 4; MediMabs, Montreal, Canada). It was
generated against rat purified DBH. The specificity was
tested by Western blot, ELISA and immunocytochemis-
try and it was found that it is highly specific for rat
DbH, and does not cross-react with DbH in mouse,
human, rabbit, bovine, guinea pig or cat tissues [78].
S100b: A rabbit polyclonal antibody purchased from
Swant (Code Number 37A). It was generated against
purified bovine brain S100b and shows < 0.5% cross-
reactivity with S100a and reacts with S100b from all
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species (i.e. bovine, rat, chicken and human) (data
obtained from supplier). This antibody has been used as
a marker for Schwann cells [79].
P75: The monoclonal antibody against the low-affinity
neurotrophin receptor (MC192, Novus Biologicals, Lit-
tleton, CO) was generated from solubilized rat PC12 cell
membranes and was found to be selective towards rat
p75 to the exclusion of gerbil, hamster, guinea pig or
mouse p75 [80]. Its distribution in rat skin was
described at both light microscopic and electron micro-
scopic levels [16]
TrkA: Monoclonal anti-TrkA (R&D Systems
MAB1056 Clone: 315104 Lot #WPO0108021) raised
against recombinant rat TrkA extracellular domain (a.a.
33-418). This antibody recognized rrTrkA by ELISA and
Western Blot with no cross-reactivity towards recombi-
nant human TrkA, TrkB, TrkC, recombinant mouse
TrkB and TrkC (information provided by supplier).
PGP 9.5: The rabbit anti-PGP 9.5 antibody (Ultraclone
code RA95101) was generated by repeated injection of
purified whole human PGP 9.5 in Freund’s adjuvant into
rabbits. The antibody cross-reacts with PGP 9.5 protein
in all mammalian species (manufacturer’s technical
information). By Western blot, it recognizes a band at
38 kDa from human and rat skin, and preadsorption
with purified PGP 9.5 completely abolished this recogni-
tion [81,82]. Immunohistochemical staining with this
antibody in either rat or human skin was absent follow-
ing preadsorption with purified human PGP 9.5 protein
[81,82].
proNGF: The rabbit anti-proNGF antibody (Alomone
#ANT-005 Lot#AN-03) was generated by injection of a
synthetic peptide corresponding to a.a. 84-104 of the
precursor form of rat NGF. It cross-reacts with rat,
mouse and human proNGF (information from supplier).
Western Blot
Samples were kept at -20°C until manually homogenized
with liquid nitrogen and added to RIPA buffer (1% NP-
40, 1% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate, 150 mM NaCl, 25 mL Tris-HCl, pH 7.6) containing
protease inhibitors (Complete, Roche Molecular Bio-
chemicals, Indianapolis, IN). Samples were agitated
overnight at 4°C, followed by 45 minute centrifugation
at 13,200 rpm to separate supernatant. The supernatant
was pipetted and protein quantified using Bio-Rad DC
Protein Assay (Bio-Rad, Mississauga Ont). Samples were
then prepared as either reduced (in the case of TrkA
and proNGF) or not (in the case of p75) using 10% b-
mercaptoethanol (Bio-Rad, Mississauga Ont) SDS-based
protein loading buffer. Samples were then boiled for 5
min and 50 mg total protein for p75 westerns and 75
mg total protein for proNGF and TrkA westerns were
loaded onto a 4% stacking and 12% separating
acrylamide gel for SDS-PAGE at 90 V. Samples were
transferred to nitrocellulose membranes for 90 minutes
at 110 mA and blocked for one hour. Primary antibodies
such as mouse anti-TrkA (1:500, MAB1056, R&D Sys-
tems, Minneapolis, MN), rabbit anti-proNGF (1:500,
ANT-005, Alomone Labs, Isreal), or mouse anti-p75
(1:200, MC192, Novus Biologicals) were incubated over-
night in blocking buffer at 4°C. The following day,
membranes were washed with tris-buffered saline with
0.1% Tween-20 (TBS-T) and incubated for two hours at
room temperature with secondary antibodies raised
against either mouse (Product no.: 715-035-151) or rab-
bit (Product no.: 711-035-152) IgG, conjugated to horse-
radish peroxidase (1:5000, Jackson ImmunoResearch,
West Grove PA), and incubated for one minute with
ECL substrate (Western Lighting, Perkin Elmer, Mon-
treal, Qc). Following x-ray film exposure, membranes
were incubated for one hour with stripping buffer,
blocked and incubated with mouse anti b-actin primary
antibody (1:400, A5441, Sigma) in blocking buffer for
one hour washed with TBS-T and incubated with anti-
mouse IgG-HRP (1:5000). Immunoreactive bands were
quantified by simultaneously obtaining equally sized
bands and quantification was based on optical density
and normalized against the loading control (b-actin)
using MCID Image Analysis software (MCID4 Image
Analysis System; Imaging Research Inc.; St Catherine’s
ON, Canada).
Images for the Figures
Pictures for the figures of this publication were taken as
Z-stacks of confocal optical sections using a Zeiss LSM
510 confocal microscope equipped with argon and
helium neon lasers applying a 40X water-immersion
objective. Images were originally saved in the Zeiss for-
mat, then exported directly into the TIFF format and
adjusted for brightness and contrast only, using Adobe
Photoshop CS4. Bright field images were taken using a
Zeiss Axioplan 2 imaging microscope equipped with a
40 × Plan-Fluotar oil-immersion objective. Images were
acquired with a high-resolution color digital camera
using the Zeiss AxioVision software. Representative
images of Western Blots were taken using an Epson
scanner, saved as TIFF format and realigned using
Adobe Photoshop CS4.
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